Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study

Inflammatory Bowel Diseases

Volumn 20, Issue 12, 2014, Pages 2247-2259

  Dotan, Iris ^a,b   Ron, Yulia ^a,b   Yanai, Henit ^a,b   Becker, Stuart ^a,b   Fishman, Sigal ^a,b   Yahav, Lior ^a,b   Yehoyada, Merav Ben ^a,b   Mould, Diane R ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Projections Research Inc   (United States)

Author keywords

Biologic therapies; Half life; Pharmacology; Trough levels

Indexed keywords

ALBUMIN; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID; DRUG ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; BODY MASS; BODY WEIGHT; CHILL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FEVER; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; REMISSION; SMOKING; ULCERATIVE COLITIS; URTICARIA; VOLUME OF DISTRIBUTION; ADOLESCENT; CHILD; FOLLOW UP; HALF LIFE TIME; INFLAMMATORY BOWEL DISEASES; ISRAEL; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; TEACHING; TISSUE DISTRIBUTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHILD; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HALF-LIFE; HUMANS; INFLAMMATORY BOWEL DISEASES; ISRAEL; MALE; MIDDLE AGED; PATIENT SIMULATION; PROGNOSIS; PROSPECTIVE STUDIES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84925759693     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000212     Document Type: Article

References (61)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337: 1029-1035.
2. Hanauer S, Feagan B, Lichtenshtein G, et al. Maintenance infliximab for Crohn's Disease: the ACCENT 1 randomized trial. Lancet. 2002;359: 1541-1549.
3. Present D, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
5. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology. 2005;128:1805-1811.
6. Laharie D, Bourreille A, Branche J, et al; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012; 380:1909-1915.
7. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of followup in the TREAT™ registry. Am J Gastroenterol. 2012;107:1409-1422.
8. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulatortreated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063.
9. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-a) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013; 108:99-105.
10. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503.
11. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
12. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol. 2013;6:269-293.
13. Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Ther Adv Gastroenterol. 2009;2:244-251.
14. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355-366.
15. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011;60:41-48.
16. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
17. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007;66:253-256.
18. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313:578-585.
19. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassay as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944-948.
20. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
21. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-1610.
22. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:447-459.
23. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40-47.
24. Vande Casteele N, Gils A, Singh S, et al. Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient. Am J Gastroenterol. 2013;108:962-971.
25. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
26. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
27. Boeckmann AJ, Beal SL, Sheiner LB. NONMEM Users Guide. Parts I-VIII. San Fransisco, CA: Icon Development Solutions; 2012.
28. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokineticpharmacodynamic models. J Pharmacokinet Biopharm. 1992;20:511-528.
29. Mould DR, Upton RN. Basic concepts in population modeling, simulation and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.
30. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481-504.
31. Jonsson EN, Karlsson MO. Xpose-An SPLUS based population pharmacokinetic-pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
32. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the predictive check. J Pharmacokinet Pharmacodyn. 2001; 28:171-192.
33. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20.
34. Xu Z, Mould DR, Hu C, et al. Population pharmacokinetic analysis of infliximab in pediatrics using integrated data from six clinical trials. Clin Pharmacol Drug Dev. 2012;1:203.
35. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211-1228.
36. Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48:297-308.
37. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-529.
38. Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946-964.
39. Kevans D, Murthy S, Iacono A, et al. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology. 2012;142(suppl 1):S-384-S-385.
40. Karagiannides I, Pothoulakis C. Neuropeptides, mesenteric fat, and intestinal inflammation. Ann N Y Acad Sci. 2008;1144:127-135.
41. Bhalme M, Sharma A, Keld R, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease? Eur J Gastroenterol Hepatol. 2013;25:543-549.
42. Ottaviani S, Allanore Y, Tubach F, et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther. 2012; 14:R115.
43. Gremese E, Carletto A, Padovan M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor a in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res. 2013;65:94-100.
44. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
45. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
46. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767.
47. Requeiro M, Siemanowski B, Kip K, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007;13:1093-1099.
48. Steenholdt C, Al-Khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2209-2217.
49. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444-447.
50. Vande Casteele N, Buurman DJ, Sturkenboom MGG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 36:765-771.
51. Kopylov U, Mazor Y, Yavzori M, et al. The clinical utility of anti human lambda chain-based ELISA versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis. 2012;18:1628-1633.
52. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
53. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451-1459.
54. Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012;18:2026-2033.
55. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919-927.
56. de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353-358.
57. Russo EA, Harris AW, Campbell S, et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther. 2009;29:308-314.
58. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut. 2009;58:492-500.
59. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7:736-743.
60. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721-1727.
61. Ordás I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079-1087.